SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Schiffman M, Kjaer SK. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;(31):14-19.
  • 2
    Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 2010;162:1269-1277.
  • 3
    Scholefield JH, Castle MT, Watson NF. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg. 2005;92:1133-1136.
  • 4
    Watson AJ, Smith BB, Whitehead MR, Sykes PH, Frizelle FA. Malignant progression of anal intra-epithelial neoplasia. ANZ J Surg. 2006;76:715-717.
  • 5
    de Pokomandy A, Rouleau D, Ghattas G, et al. HAART and progression to high-grade anal intraepithelial neoplasia in men who have sex with men and are infected with HIV. Clin Infect Dis. 2011;52:1174-1181.
  • 6
    Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407-1414.
  • 7
    Palefsky JM, Holly EA, Ralston ML, Jay N, Berry JM, Darragh TM. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12:495-503.
  • 8
    Severini A. Anal intraepithelial neoplasia in men living with HIV in the era of highly active antiretroviral therapy. Clin Infect Dis. 2011;52:1182-1183.
  • 9
    Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207; quiz CE1-CE4.
  • 10
    San Francisco Department of Public Health HIV/AIDS Epidemiology Annual Report. HIV Epidemiology Section. sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2011.pdf. Accessed June 25, 2013.
  • 11
    Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML. High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum. 2008;51:829-835; discussion 835-837.
  • 12
    Darragh TM, Colgan TJ, Cox JT, et al; Members of the LAST Project Work Groups. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med. 2012;136:1266-1297.
  • 13
    Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non–AIDS-defining cancers among adults with AIDS. Am J Epidemiol. 2007;165:1143-1153.
  • 14
    Katz KA, Clarke CA, Bernstein KT, Katz MH, Klausner JD. Is there a proven link between anal cancer screening and reduced morbidity or mortality? Ann Intern Med. 2009;150:283-284; author reply 284-285.
  • 15
    Watson M, Saraiya M, Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113(suppl 10):2841-2854.
  • 16
    Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer. 2008;113(suppl 10):2892-2900.
  • 17
    Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999. Prev Med. 2003;36:555-560.
  • 18
    Surveillance Research Program, National Cancer Institute. SEER*Stat software. Version 7.0.5. seer.cancer.gov/seerstat. Accessed June 25, 2013.
  • 19
    Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19:335-351.
  • 20
    Rothman J, Greenland S, Lash T. Modern Epidemiology. Philadelphia, PA: Lippincott Williams and Wilkins; 2008.
  • 21
    Surveillance Systems Branch, Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. SEER Program Coding and Staging Manual. seer.cancer.gov/manuals/2011/SPCSM_2011_maindoc_09272011.pdf. Accessed June 25, 2013.
  • 22
    Saraiya M, Goodman MT, Datta SD, Chen VW, Wingo PA. Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role. Cancer. 2008;113(suppl 10):3047-3057.
  • 23
    Xia Q, Nonoyama A, Molitor F, Webb D, Osmond D. Recent decline in the incidence of human immunodeficiency virus infection among California men who have sex with men. Am J Epidemiol. 2011;174:203-210.
  • 24
    Hernandez AL, Efird JT, Holly EA, Berry JM, Jay N, Palefsky JM. Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco [published online ahead of print April 22, 2013]. J Acquir Immune Defic Syndr.
  • 25
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13 through 17 years–United States, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:1117-1123.
  • 26
    Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24.
  • 27
    Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626-629.
  • 28
    Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1705-1708.
  • 29
    Centers for Disease Control and Prevention (CDC). National and state vaccination coverage among adolescents aged 13-17 years- United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:671-677.
  • 30
    Goldie SJ, Kuntz KM, Weinstein MC, Freedberg KA, Welton ML, Palefsky JM. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-1829.
  • 31
    Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43:223-233.
  • 32
    Salit IE, Tinmouth J, Chong S, et al. Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology. Cancer Epidemiol Biomarkers Prev. 2009;18:1986-1992.
  • 33
    Amirian ES, Fickey PA Jr, Scheurer ME, Chiao EY. Anal cancer incidence and survival: comparing the greater San-Francisco bay area to other SEER cancer registries. PLoS One. 2013;8:e58919.
  • 34
    Park IU, Palefsky JM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep. 2010;12:126-133.